Evofem Biosciences Inc (EVFM)


Stock Price Forecast

Sept. 9, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Evofem Biosciences Inc chart...

About the Company

Evofem Biosciences, Inc., is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, 'EVOGUARD,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women.

CEO

Saundra Pelletier

Exchange

NASDAQ

Website

www.evofem.com

$15M

Total Revenue

147

Employees

$27M

Market Capitalization

-0.06

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $EVFM News

Aditxt Announces Merger Agreement with Evofem Biosciences

1mon ago, source: Hosted on MSN

Aditxt, Inc. has entered into a Merger Agreement with its subsidiary Adicure, Inc. and Evofem Biosciences, Inc., with subsequent amendments extending key dates relating to a joint proxy statement ...

Evofem Biosciences Inc EVFM

26d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Evofem Biosciences, Inc.: Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

1mon ago, source: Finanznachrichten

2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced strong preliminary, unaudited results for fiscal 2023, including record net sales of Phexxi ® (lactic acid, citric acid ...

Pearsanta acquires MDNA for $25M

1mon ago, source: BioWorld

The company moved into the women’s health market with the $100 million planned acquisition of Evofem Biosciences Inc., maker of the contraceptive gel Phexxi, which it reported on Dec. 12. The deals ...

Aditxt, Inc. (ADTX) stock price, news, quote & history – Yahoo Finance

6mon ago, source: Yahoo Finance

Evofem Biosciences, Inc. (OTCQB: EVFM) today announced strong preliminary, unaudited results for fiscal 2023, including record net sales of Phexxi® (lactic acid, citric acid, and potassium bitartrate) ...

Evofem Biosciences Announces Merger Agreement with Aditxt

1mon ago, source: Hosted on MSN

Evofem Biosciences, Inc. has entered into a Merger Agreement with Aditxt, Inc. and its subsidiary, which has been amended twice, altering the timelines for a joint proxy statement and a Parent ...

Evofem Biosciences, Inc. (EVFM)

1mon ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

1mon ago, source: ADVFN

About Evofem Biosciences Evofem Biosciences, Inc., (OTCQB: EVFM) is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA ...

EVFM Evofem Biosciences, Inc.

17d ago, source: Seeking Alpha

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Evofem Biosciences Inc (EVFM)

1mon ago, source: Investing

Mersana Therapeutics, Inc. (NASDAQ:MRSN) exploded on Wednesday and had a big follow-through on Thursday, with a pop of 1.50, or 8.25%, to 19.69, after reaching a multi-week and ...

Evofem Biosciences, Inc. (EVFM)

5d ago, source: Yahoo Finance

*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...